BMS 986195

Drug Profile

BMS 986195

Alternative Names: BMS986195

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 04 Oct 2017 Phase-I clinical trials in Rheumatoid arthritis (In volunteers, In adults) in USA (PO) (NCT03262740)
  • 29 Aug 2017 Bristol-Myers Squibb plans a phase I trial in Healthy volunteers (NCT03262740)
  • 16 Aug 2017 Bristol-Myers Squibb completes a phase I trial in Healthy volunteers in Australia (PO) (NCT02705989)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top